The functional roles and therapeutic potential of protein palmitoylation in hepatocellular carcinoma Authors: Fang Wei, Zi Qing Zhu, Yu Meng, Yueping Shen, Dan-Xia Zhu, Jun Wu Published: 2026 ABSTRACT AbstractObjectiveProtein palmitoylation is a reversible lipid post-translational modification that influences protein stability, membrane association, and signal transduction. Increasing evidence indicates that dysregulated palmitoylation contributes to tumor development by altering the activity of oncogenes, tumor suppressors, transcription factors, and membrane proteins, as well as by reshaping the tumor microenvironment. However, the biological significance of this modification in hepatocellular carcinoma (HCC) has not yet been fully clarified. This review summarizes current knowledge of palmitoylation-mediated regulation in HCC and evaluates its potential as a therapeutic target.MethodsRelevant studies were identified through systematic searches of PubMed and Web of Science using keywords including “protein palmitoylation,” “post-translational modification,” “hepatocellular carcinoma,” and “tumor therapy.” Published evidence was analyzed to examine the roles of palmitoylation in HCC cell proliferation, apoptosis, migration, invasion, and associated signaling pathways.ResultsAccumulating evidence indicates that protein palmitoylation contributes to hepatocellular carcinoma progression by modulating the activity and localization of key signaling proteins, including Ras, AKT, and YAP. Through these regulatory effects, palmitoylation influences multiple oncogenic pathways such as Wnt/β-catenin, PI3K/AKT/mTOR, Hippo/YAP, and STAT3 signaling. In addition, metabolic regulatory circuits, including the FASN-ZDHHC-20 and PHF2-SREBP1c axes, link lipid metabolism with palmitoylation-dependent signaling in HCC. Emerging pharmacological approaches targeting palmitoylation-related enzymes-such as palmitoyltransferases and depalmitoylases—have shown promising antitumor activity in preclinical studies.ConclusionProtein palmitoylation represents an important regulatory layer in hepatocellular carcinoma biology, integrating lipid metabolism with oncogenic signaling networks. Therapeutic strategies targeting enzymes that control palmitoylation dynamics may therefore offer new opportunities for HCC treatment. Future investigations should focus on defining the substrate specificity and regulatory mechanisms of individual ZDHHC enzymes, PATs, and depalmitoylases to facilitate the development of more selective therapeutic interventions.Keywords: Palmitoylation, Hepatocellular carcinoma, Cellular signaling pathways, Cancer therapeutic targets, Tumor immune microenvironment Introduction Hepatocellular carcinoma (HCC) is the most prevalent subtype of primary liver cancer and represents one of the leading causes of cancer‑related mortality worldwide. Despite advances in surgical resection, targeted therapy, and immunotherapy, the overall prognosis for patients with advanced HCC remains poor. The high mortality rate largely results from late diagnosis, rapid tumor progression, and resistance to systemic therapies [1, 2]. Understanding the molecular mechanisms that drive hepatocarcinogenesis is therefore critical for developing new therapeutic strategies. Accumulating evidence indicates that post‑translational modifications (PTMs) play crucial roles in regulating oncogenic signaling pathways in cancer. Among these modifications, protein palmitoylation has emerged as an important regulatory mechanism controlling protein trafficking, membrane association, and signal transduction [3]. Among these, protein palmitoylation has emerged as a critical regulatory mechanism, yet its association with HCC progression remains relatively understudied compared to other malignancies [4–10]. Protein palmitoylation represents a lipid modification in which palmitic acid is covalently attached to specific amino acid residues of target proteins. Depending on the chemical linkage formed between palmitate and the protein backbone, palmitoylation can be classified into S-, O-, and N-linked forms. Among these categories, S-palmitoylation, which involves a thioester bond between palmitate and cysteine residues, is the predominant type identified in eukaryotic cells. A distinctive feature of this modification is its reversible nature, allowing proteins to undergo cycles of palmitoylation and depalmitoylation that dynamically regulate their subcellular localization and signaling functions [11]. The palmitoylation cycle is primarily controlled by two opposing enzyme families. Palmitoyltransferases of the zinc‑finger DHHC domain‑containing (ZDHHC) family catalyze the addition of palmitate to substrate proteins, whereas depalmitoylating enzymes, including acyl‑protein thioesterases (APTs), palmitoyl‑protein thioesterases (PPTs), and ABHD family proteins, remove this modification. Through the coordinated activity of these enzymes, palmitoylation dynamically regulates the stability and signaling activity of numerous proteins [12–14]. In cancer biology, palmitoylation has been shown to regulate multiple oncogenic pathways and cellular processes, including proliferation, apoptosis, migration, metabolic reprogramming, and immune evasion. In hepatocellular carcinoma, recent studies have demonstrated that palmitoylation modulates key oncogenic proteins such as RAS, AKT, STAT3, and YAP, thereby influencing tumor progression [15–18]. Furthermore, palmitoylation also plays a critical role in shaping the tumor immune microenvironment by stabilizing immune checkpoint molecules [19–21], but its context-specific roles in HCC remain incompletely defined. S-palmitoylation, distinct from the relatively rare and irreversible N- and O-palmitoylation, will be the primary focus of this review. In this review, we summarize current knowledge regarding the biological functions of protein palmitoylation in hepatocellular carcinoma. We discuss how palmitoylation regulates major oncogenic signaling pathways, explore its role in metabolic and immune regulation, and evaluate the therapeutic potential of targeting palmitoylation in HCC. The overall regulatory framework of palmitoylation signaling in HCC is summarized in Fig. 1. The palmitoylation network in hepatocellular carcinoma. This schematic illustrates the dynamic cycle of protein S-palmitoylation mediated by ZDHHC palmitoyltransferases and depalmitoylases (APT/PPT/ABHD family). By regulating protein membrane localization, stability, and protein–protein interactions, palmitoylation modulates multiple oncogenic signaling pathways, including Wnt/β-catenin, PI3K/AKT/mTOR, Hippo/YAP, and STAT3, FASN–ZDHHC-20, PHF2–SREBP1c Axis. HCC Hepatocellular Carcinoma; ZDHHC Zinc Finger DHHC-Type Palmitoyltransferase; APT Acyl Protein Thioesterase; PPT Palmitoyl Protein Thioesterase; ABHD17 Abhydrolase Domain Containing 17; FASN Fatty Acid Synthase; PHF2 PHD Finger Protein 2; SREBP1c Sterol Regulatory Element-Binding Protein 1c. (This figure was created by Figdraw) Biological functions of palmitoylation in hepatocellular carcinoma Protein palmitoylation regulates diverse biological processes that contribute to HCC progression. Protein palmitoylation functions as an important regulatory layer that modulates signal transduction by controlling protein localization, stability, and interaction with signaling complexes. In HCC, palmitoylation can act as a signaling amplifier, enhancing the activity of oncogenic pathways by stabilizing key signaling proteins or facilitating their recruitment to membrane signaling platforms. Through this mechanism, palmitoylation contributes to the activation of multiple pathways that drive tumor proliferation, survival, and metastasis [22]. Regulation of tumor cell proliferation Palmitoylation plays a critical role in controlling the activity of several oncogenic signaling proteins that drive tumor cell proliferation. Members of the RAS family represent classical examples of palmitoylation‑regulated oncogenic proteins. Among the four RAS isoforms produced by three human genes (HRAS, NRAS, KRAS4A, and KRAS4B), HRAS, NRAS, and KRAS4A undergo reversible S-palmitoylation at cysteine residues near their C-termini, which regulates their dynamic association with cellular membranes and signaling activity. In contrast, KRAS4B lacks this palmitoylation modification and instead relies on an alternative mechanism for membrane targeting [23]. In hepatocellular carcinoma, aberrant activation or mutation of RAS signaling is frequently observed. Palmitoylation facilitates the membrane association of RAS proteins and promotes activation of downstream signaling cascades, particularly the MAPK/ERK pathway, thereby enhancing proliferative signaling. The palmitoyltransferase ZDHHC-9 plays a key role in catalyzing the palmitoylation of HRAS and NRAS, a modification required for their proper membrane localization and oncogenic function. Disruption of ZDHHC-9 activity—either through genetic alteration or reduced expression—can impair RAS palmitoylation, weaken plasma membrane targeting, and consequently attenuate downstream signaling and tumorigenic potential [24]. Notably, palmitoylation does not universally promote tumor progression; in certain contexts, it can exert tumor-suppressive effects. The oncogenic protein AEG-1 (astrocyte elevated gene-1) provides an illustrative example. Recent studies have shown that AEG-1 undergoes reversible palmitoylation at the conserved cysteine residue Cys75, a process coordinated by the palmitoyltransferase ZDHHC6 and the depalmitoylases PPT1/2. This modification negatively regulates AEG-1 stability and weakens its interaction with staphylococcal nuclease and Tudor domain-containing protein 1 (SND1), thereby modulating RNA-induced silencing complex (RISC) activity and facilitating the expression of tumor-suppressive genes. Consistent with this regulatory role, inhibition of AEG-1 palmitoylation has been shown to accelerate hepatocellular carcinoma progression in vivo, highlighting the context-dependent tumor-suppressive potential of this modification [25]. Additional evidence further links lipid metabolism to palmitoylation-driven oncogenic signaling. Palmitic acid (PA) supplementation has been reported to increase the expression of ZDHHC-12 through activation of the transcription factor SMARCA4, a core ATPase component of the SWI/SNF chromatin remodeling complex. Elevated ZDHHC-12 subsequently catalyzes palmitoylation of HDAC8 at cysteine 244 (Cys244), which prevents its lysosomal degradation and ultimately contributes to hepatocellular carcinoma progression [26]. Regulation of apoptosis Protein palmitoylation also contributes to the regulation of hepatoma cell survival by influencing apoptosis-related signaling pathways. One important mechanism involves the control of death receptor trafficking and membrane localization. Fas (CD95/APO-1), a member of the tumor necrosis factor receptor (TNFR) superfamily, initiates apoptotic signaling following engagement with its ligand FasL or agonistic antibodies. Previous studies have shown that the palmitoyltransferase ZDHHC-7 catalyzes palmitoylation of Fas at Cys199, a modification required for proper receptor localization and functional signaling. Disruption of this modification impairs Fas membrane targeting and destabilizes the receptor, thereby reducing cellular sensitivity to FasL-induced apoptosis [27]. In addition to ZDHHC-7, other palmitoyltransferases may also participate in regulating apoptosis-related pathways in cancer. For example, depletion of ZDHHC-20 has been reported to alter palmitoylation dynamics and suppress tumor growth. Mechanistically, enhanced palmitoylation mediated by ZDHHC-20 has been associated with increased proliferative and metastatic capacity of tumor cells, accompanied by attenuation of apoptotic signaling pathways [28]. Regulation of tumor cell migration and invasion Metastasis is a major contributor to the poor prognosis of hepatocellular carcinoma. Emerging evidence suggests that protein palmitoylation participates in the regulation of tumor cell migration and invasion by influencing cytoskeletal organization and cell–matrix interactions. One representative example is synaptosomal-associated protein-23 (SNAP-23), which contains several conserved cysteine residues within its central region that can undergo palmitoylation. This lipid modification promotes stable membrane association of SNAP-23 and facilitates vesicle trafficking and cytoskeleton-related processes, thereby supporting pseudopodia formation and cell motility [29]. Palmitoylation can also regulate cell adhesion signaling. For instance, palmitoylation of integrin receptors enhances their capacity to interact with extracellular matrix components, which contributes to increased invasive potential of tumor cells [30]. Palmitoylation can also regulate cell adhesion signaling. For instance, palmitoylation of integrin receptors enhances their capacity to interact with extracellular matrix components, which contributes to increased invasive potential of tumor cells [31]. Collectively, these findings suggest that palmitoylation acts as a regulatory layer controlling membrane organization and adhesion signaling, thereby shaping the metastatic behavior of hepatocellular carcinoma cells. Regulation of the tumor microenvironment Recent progress in immunotherapy has significantly improved the treatment landscape of HCC, with a subset of patients achieving durable clinical responses. Nevertheless, the overall therapeutic benefit remains limited due to relatively low response rates and the occurrence of immune-related adverse events. Increasing evidence indicates that the effectiveness of immunotherapeutic strategies is closely associated with the composition and functional state of the tumor immune microenvironment (TIME). Emerging studies suggest that protein palmitoylation represents an important regulatory mechanism in shaping the TIME by influencing immune cell activity, cytokine signaling, and immune checkpoint stability. Understanding how palmitoylation orchestrates these immunological processes may therefore provide new opportunities to enhance the efficacy of immunotherapy through targeted modulation of this lipid modification [32]. Experimental studies further support a link between palmitoylation-associated lipid metabolism and immune regulation in HCC. In HepG2 cells, palmitic acid (PA) has been shown to promote tumor progression through multiple mechanisms, including enhancement of cancer stem cell characteristics, increased intracellular oxidative stress, and elevated expression of pro-inflammatory mediators such as TNF-α, IL-6, and intercellular adhesion molecule-1 (ICAM-1). These alterations contribute to the establishment of a pro-tumorigenic microenvironment [33]. In addition, palmitoylation influences tumor immunity by regulating the stability and activity of immune checkpoint proteins. For instance, palmitoylation of programmed death ligand-1 (PD-L1) enhances its protein stability, thereby strengthening its ability to suppress T-cell-mediated anti-tumor responses. The interaction between PD-1 on T cells and PD-L1 on tumor cells forms a central immune checkpoint pathway that maintains immune homeostasis, while its dysregulation facilitates tumor immune escape [34–36]. Beyond its canonical immune regulatory role, PD-1 may also participate directly in tumor cell signaling. Studies have shown that PD-1 can promote tumor growth through activation of the mammalian target of rapamycin (mTOR) pathway [37]. Further mechanistic investigation revealed that palmitoylation enhances the interaction of PD-1 with downstream mTOR effectors such as S6 and eIF4E, thereby promoting mTOR pathway activation and tumor progression. ZDHHC-9 has been identified as the principal palmitoyltransferase responsible for PD-1 modification in tumor cells. Importantly, inhibition of PD-1 palmitoylation, either genetically or pharmacologically, reduces PD-1 surface expression and suppresses tumor growth, highlighting this modification as a promising therapeutic target for cancer immunotherapy [38]. Palmitoylation also regulates the stability of additional immune checkpoint molecules. The checkpoint receptor TIM-3 undergoes ZDHHC9-mediated palmitoylation at Cys296, which prevents its recognition by the E3 ubiquitin ligase HRD1 and thereby protects TIM-3 from proteasomal degradation. Disruption of this modification promotes TIM-3 degradation and alleviates immune cell exhaustion. Consistent with this mechanism, inhibition of ZDHHC-9 has been shown to restore the cytotoxic activity of both CAR-T cells and natural killer (NK) cells. Clinical analyses further revealed a positive correlation between ZDHHC-9 expression and TIM-3 levels in tumor-infiltrating CD8⁺ T cells and NK cells from HCC patients, and the simultaneous high expression of these proteins is associated with poorer patient prognosis [39]. These findings indicate that ZDHHC9-dependent palmitoylation contributes to immune suppression by stabilizing TIM-3 and promoting T-cell exhaustion within the tumor microenvironment. However, immune checkpoint regulation is highly complex and involves multiple signaling pathways and cellular interactions within the tumor microenvironment [40]. Consequently, the therapeutic benefit of targeting TIM-3 palmitoylation will likely depend on the broader immune context and the presence of other checkpoint pathways. In addition to ZDHHC-9, other palmitoyltransferases also participate in immune regulation in HCC. ZDHHC-20 has been proposed as a key regulator of immunosuppressive signaling, as its overexpression promotes the recruitment of regulatory T cells and myeloid-derived suppressor cells while increasing the expression of immune checkpoint molecules such as PD-1 and CTLA-4 [28]. These changes collectively contribute to the formation of an immunologically “cold” tumor microenvironment that is less responsive to immunotherapy. Moreover, palmitoylation of vascular endothelial growth factor (VEGF) receptors enhances receptor signaling and promotes tumor angiogenesis, further supporting tumor growth and immune evasion [41]. Beyond its mechanistic role in stabilizing immune checkpoint proteins, palmitoylation-dependent regulation of PD-1 and PD-L1 may have important implications for immunotherapy. Current immune checkpoint blockade therapies show limited response rates in hepatocellular carcinoma, partly due to heterogeneous expression of checkpoint molecules and adaptive resistance mechanisms within the tumor microenvironment. Systemic inhibition of palmitoylation enzymes may also affect immune cell function in normal tissues, potentially leading to unintended immunological consequences [42]. Therefore, future therapeutic strategies may need to focus on substrate-selective inhibition or tumor-specific targeting to enhance immunotherapy efficacy while minimizing immune-related toxicity. Collectively, current evidence suggests that palmitoylation plays an important role in shaping the tumor microenvironment of hepatocellular carcinoma. By regulating immune checkpoint proteins, inflammatory signaling pathways, and angiogenic factors, palmitoylation contributes to immune evasion and tumor progression. These findings highlight the potential of palmitoylation as a regulatory interface linking tumor-intrinsic signaling with immune microenvironment remodeling. Nevertheless, the precise mechanisms through which palmitoylation influences immune cell function and tumor–immune interactions remain to be fully elucidated. Palmitoylation drives the core mechanism of liver cancer Protein palmitoylation regulates multiple oncogenic signaling pathways involved in HCC progression. The major palmitoylation-regulated signaling networks involved in hepatocellular carcinoma progression are summarized in Fig. 2. Key palmitoylated proteins and their associated palmitoyltransferases that have been reported in HCC are summarized in Table 1, highlighting the diverse substrates and regulatory mechanisms involved in palmitoylation-dependent tumor signaling. Network of palmitoylation-regulated oncogenic signaling in hepatocellular carcinoma. This schematic illustrates the central signaling pathways dysregulated in HCC and highlights the regulatory roles of specific ZDHHC palmitoyltransferases within this network. Protein S-palmitoylation events, catalyzed by the indicated ZDHHC enzymes (e.g., ZDHHC-16, -20), are shown to critically modulate pathway activity (such as Wnt/β-catenin, PI3K/AKT/mTOR, Hippo/YAP, STAT3, FASN-ZDHHC20, PHF2-SREBP1c Axis)by affecting the stability, localization, or interactions of key components. APC Adenomatous Polyposis Coil; AXIN Axis Inhibition Protein; DVL Dishevelled; FASN Fatty Acid Synthase; FZD Frizzled; GSK-3β Glycogen Synthase Kinase 3 Beta; HCC Hepatocellular Carcinoma; HIF-1α Hypoxia-Inducible Factor 1-Alpha; IL-6 Interleukin-6; JAK2 Janus Kinase 2; LRP LDL Receptor-Related Protein; mTOR Mechanistic Target of Rapamycin; PI3K Phosphoinositide 3-Kinase; PIP2/3 Phosphatidylinositol (4,5)-bisphosphate / (3,4,5)-trisphosphate; PHF2 Plant Homeodomain Finger Protein 2; PORCN Porcupine O-Acyltransferase; PTEN Phosphatase and TENsin homolog; SCRIB Scribble Polarity Protein; SREBP1c Sterol Regulatory Element-Binding Transcription Factor 1c; STAT3 Signal Transducer and Activator of Transcription 3; TCF/LEF T-cell Factor/Lymphoid Enhancer Factor; TME Tumor Microenvironment; YAP/TAZ Yes-Associated Protein/Transcriptional Coactivator with PDZ-binding motif; ZDHHC Zinc Finger DHHC-Type Palmitoyltransferase. (This figure was created by Figdraw) Table 1Key oncogenic drivers under palmitoylation controlProteinZDHHC enzymeFunctional consequence in HCCEvidence levelReferencesPrimary oncogenic driversRASZDHHC-9Promotes GTP loading, membrane localization, and MAPK signaling; drives proliferation.In vitro, In vivo[23, 24]YAP/TAZZDHHC-7/9Facilitates nuclear translocation and transcriptional co-activation; promotes proliferation and stemness.In vitro[49]STAT3ZDHHC-7/19Promotes dimerization, nuclear translocation, and transcriptional activity of oncogenic genes, driving proliferation and survival.In vitro, In vivo[50, 51]AKTZDHHC-7/17/24Augments membrane recruitment and phosphorylation; suppresses apoptosis.In vitro[18, 44–46, 49]Secondary modifiers or substratesPD-L1ZDHHC-9Stabilizes protein, enhances immune evasion.In vitro, In vivo[38]TIM-3ZDHHC-9Stabilizes the protein on T cells or tumor cells, contributing to T-cell exhaustion and immune evasion.In vitro[39]FasZDHHC-7Palmitoylation is required for its apoptotic function. Loss of palmitoylation may aid immune evasion, but it does not directly drive oncogenesis.In vitro[27]HDAC8ZDHHC-12Impaires lysosomal degradation, enhancing its oncogenic activity to accelerate tumor progression.In vitro[58]PCSK9ZDHHC-16Regulates protein stability and secretion; modulates cholesterol homeostasis.In vitro, In vivo[46]PHF2ZDHHC-23Stabilizes SREBP1c to drive lipogenesis and metabolic reprogramming.In vitro, In vivo[57] Key oncogenic drivers under palmitoylation control Wnt/β-catenin signaling pathway Palmitoylation controls Wnt ligand maturation and pathway activation in HCC. Wnt proteins constitute a group of highly conserved secreted glycoproteins that regulate intercellular communication through both autocrine and paracrine signaling. These signaling molecules are essential for controlling key biological processes, including cell proliferation, lineage differentiation, and maintenance of stem cell properties. Dysregulation of Wnt signaling has been widely implicated in tumorigenesis, where persistent pathway activation contributes to tumor initiation, progression, and resistance to therapy. Within the Wnt signaling network, palmitoylation plays a critical role in the maturation and secretion of Wnt ligands. By regulating ligand processing and receptor interaction, palmitoylation acts as a molecular switch that determines whether Wnt signaling is activated or suppressed in tumor cells. In the absence of Wnt stimulation, intracellular β-catenin levels are tightly controlled by a multiprotein destruction complex composed of Axin, adenomatous polyposis coli (APC), and glycogen synthase kinase-3β (GSK3β). Within this complex, β-catenin undergoes phosphorylation, which marks the protein for ubiquitination and subsequent proteasomal degradation, thereby preventing transcriptional activation of Wnt-responsive genes. When Wnt ligands engage Frizzled (FZD) receptors on the cell membrane, the adaptor protein Dishevelled (Dvl) becomes activated and disrupts the destruction complex. As a result, β-catenin escapes degradation and accumulates in the cytoplasm before translocating into the nucleus, where it interacts with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to drive expression of Wnt target genes. Lipid modification by palmitoylation represents a key regulatory step in this signaling cascade. The membrane-associated O-acyltransferase Porcupine (PORCN) catalyzes palmitoylation of Wnt ligands, a modification that is essential for their secretion and biological activity. Increased PORCN expression has been reported to enhance β-catenin nuclear accumulation and transcriptional activity in hepatocellular carcinoma, thereby promoting tumor cell invasion [43]. Given its central role in Wnt ligand maturation, PORCN has emerged as a potential therapeutic target, and pharmacological inhibitors of this enzyme are currently being explored as candidate anti-cancer agents. PI3K/AKT/mTOR signaling pathway Palmitoylation enhances oncogenic PI3K/AKT signaling through membrane recruitment and protein stabilization. The PI3K/AKT signaling pathway represents one of the most frequently activated oncogenic cascades in hepatocellular carcinoma. Activation of the PI3K/AKT pathway requires precise spatial organization of signaling components at cellular membranes. Palmitoylation facilitates this process by promoting membrane recruitment of key signaling proteins, thereby enhancing pathway activation and downstream oncogenic signaling. Within this pathway, the serine/threonine kinase AKT functions as a key signaling hub that integrates upstream growth factor signals to regulate multiple cellular processes, including cell proliferation, metabolic activity, and survival [44]. Aberrant activation of the PI3K/AKT/mTOR axis has therefore been widely recognized as a major contributor to tumor development and progression. Recent studies suggest that lipid modification by palmitoylation provides an additional regulatory layer controlling this pathway. Palmitoylation influences both the subcellular localization and activation status of signaling proteins within the PI3K pathway, particularly AKT and its downstream effectors. For example, exposure to palmitic acid (PA), a major saturated fatty acid, has been shown to enhance AKT palmitoylation at cysteine residues Cys77 and Cys224 through the palmitoyltransferases ZDHHC-17 and ZDHHC-24. This modification facilitates AKT association with the plasma membrane independently of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and prevents inhibitory conformational changes mediated by the pleckstrin homology (PH) domain. As a result, AKT undergoes sustained phosphorylation at key activation sites such as Ser473, thereby stimulating downstream signaling molecules including mTOR and GSK-3β, which collectively promote hepatocyte proliferation while suppressing apoptotic signaling [18]. Experimental evidence further supports the importance of palmitoylation in PI3K pathway activation during hepatocarcinogenesis. In xenograft mouse models, genetic deletion of ZDHHC-20 significantly reduces tumor growth, indicating that this palmitoyltransferase contributes to hepatoma progression through AKT-dependent signaling mechanisms [45]. In addition to AKT itself, other regulatory proteins within this pathway are also influenced by palmitoylation. Proprotein convertase subtilisin/kexin type 9 (PCSK9), for instance, undergoes palmitoylation at cysteine 600 mediated by ZDHHC-16. This modification enhances the interaction between PCSK9 and the tumor suppressor phosphatase and tensin homolog (PTEN), promoting lysosomal degradation of PTEN. Loss of PTEN activity subsequently results in sustained phosphorylation and activation of AKT at Ser473, thereby driving uncontrolled hepatoma cell proliferation. These findings collectively highlight palmitoylation as an important modulatory mechanism that amplifies PI3K/AKT signaling in HCC [46]. Collectively, these findings suggest that palmitoylation acts as a signaling amplifier of PI3K/AKT activity in HCC. Although palmitoylation-dependent activation of AKT signaling provides an additional regulatory mechanism for PI3K pathway activation, the broader implications of this modification in hepatocellular carcinoma remain to be fully clarified. Because the PI3K/AKT pathway is frequently activated in multiple cancer types, palmitoylation-mediated modulation of AKT may represent a context-dependent regulatory mechanism rather than a universal oncogenic driver. Furthermore, targeting palmitoylation in this pathway may produce complex biological effects, as PI3K signaling also plays essential roles in normal metabolic homeostasis and immune regulation [47]. Future studies should therefore investigate whether specific tumor subtypes exhibit greater dependency on palmitoylation-mediated AKT activation, which may help identify patient populations more likely to benefit from palmitoylation-targeted therapies [48]. Hippo/YAP signaling pathway Protein palmitoylation has emerged as an important modulatory mechanism within the Hippo signaling pathway, particularly in regulating the activity of the transcriptional coactivators YAP and TAZ. In the Hippo pathway, palmitoylation contributes to the spatial organization of polarity proteins such as Scribble (SCRIB), which are essential for maintaining epithelial architecture and regulating YAP/TAZ activity. By influencing the subcellular distribution of these proteins, palmitoylation can affect their transcriptional output and consequently alter downstream gene expression programs associated with tumor development. The polarity protein SCRIB acts as an upstream regulator of Hippo signaling. Disruption or loss of SCRIB expression impairs the activation of the Hippo kinase cascade, leading to accumulation of unphosphorylated YAP/TAZ in the nucleus. Once translocated to the nucleus, YAP/TAZ interact with transcription factors to promote the expression of genes involved in cell proliferation and survival, while simultaneously enhancing oncogenic pathways such as MAPK and AKT signaling. Membrane localization of SCRIB is essential for its regulatory function in Hippo signaling. This localization depends on palmitoylation at the N-terminal cysteine residues Cys4 and Cys10, a modification that is likely mediated by the palmitoyltransferase ZDHHC-7. Through facilitating proper membrane anchoring of SCRIB, palmitoylation supports activation of the Hippo kinase cascade and contributes to the suppression of MAPK and AKT signaling pathways [49]. Nevertheless, the involvement of additional palmitoyltransferases in this regulatory process cannot be completely ruled out and warrants further investigation. These observations suggest that palmitoylation-dependent regulation of SCRIB provides an additional layer of control over Hippo signaling during hepatocellular carcinoma progression. STAT3 inflammation-tumor transformation axis Palmitoylation amplifies inflammatory STAT3 signaling and promotes HCC progression. Recent studies indicate that protein palmitoylation contributes to the regulation of inflammatory signaling pathways involved in hepatocellular carcinoma progression. In particular, ZDHHC-7-mediated palmitoylation of STAT3 at cysteine residue Cys108 enhances its transcriptional activity, thereby strengthening IL-6/STAT3-dependent inflammatory signaling that promotes tumor invasion and metastasis.Activation of this pathway begins when extracellular interleukin-6 interacts with its cell surface receptor complex, leading to activation of the Janus kinase JAK2. JAK2 subsequently phosphorylates STAT3, enabling its translocation into the nucleus where it functions as a transcriptional regulator of genes associated with tumor growth and survival. Palmitoylation further potentiates this process by increasing the transcriptional competence of STAT3. Clinical observations have shown that elevated ZDHHC-7 expression in hepatocellular carcinoma is correlated with unfavorable patient outcomes. Mechanistically, cyclin-dependent kinase 5 (CDK5) has been reported to enhance the stability of hypoxia-inducible factor-1α (HIF-1α), which subsequently promotes transcriptional upregulation of ZDHHC-7. This regulatory relationship establishes a feed-forward signaling circuit involving HIF-1α, ZDHHC-7, and STAT3 that reinforces oncogenic signaling during HCC progression. The identification of this axis suggests potential opportunities for both prognostic evaluation and therapeutic intervention [50]. In addition to ZDHHC-7, other palmitoyltransferases may also participate in STAT3 regulation. For example, amplification of ZDHHC-19 has been observed in several cancer types, and palmitoylation of STAT3 has been shown to enhance its dimerization, nuclear localization, and transcriptional activation of downstream target genes. These findings collectively highlight palmitoylation as an important regulatory layer controlling STAT3-mediated oncogenic signaling [51]. Taken together, current evidence indicates that palmitoylation enhances STAT3-mediated inflammatory signaling and thereby contributes to HCC progression. FASN-ZDHHC-20 axis Alterations in lipid metabolism are increasingly recognized as key contributors to hepatocellular carcinoma progression. Fatty acid synthase (FASN), a central enzyme responsible for de novo fatty acid synthesis, plays a critical role in generating endogenous palmitate, which provides substrates for protein palmitoylation. Elevated FASN activity can therefore enhance palmitate availability and indirectly influence palmitoylation-dependent signaling processes within tumor cells. Beyond serving as a metabolic enzyme, FASN supports malignant cell survival by supplying both energy-rich substrates and lipid components required for membrane biosynthesis during rapid tumor proliferation. The expression of FASN is tightly controlled by sterol regulatory element-binding proteins (SREBPs), which act as key transcriptional regulators of lipid metabolic pathways. By binding to regulatory elements within the FASN promoter region, SREBPs promote FASN transcription and thereby stimulate fatty acid synthesis. Conversely, pharmacological inhibition of SREBP activity suppresses FASN expression and disrupts lipid biosynthetic pathways in tumor cells [52]. Recent evidence further indicates that palmitoylation directly regulates FASN stability. ZDHHC20-mediated palmitoylation of FASN at cysteine residues C1471 and C1881 interferes with its interaction with the proteins TRIM28 and SNX8, thereby reducing ubiquitination-dependent degradation and stabilizing the FASN protein. This stabilization enhances lipid metabolic activity and contributes to hepatocellular carcinoma progression [53]. In addition to metabolic regulation, FASN has also been linked to tumor immune modulation. As an intrinsic metabolic checkpoint within cancer cells, inhibition of FASN reduces the palmitoylation of immune checkpoint protein PD-L1, leading to decreased PD-L1 stability and enhanced T cell-mediated anti-tumor responses. These findings highlight the interplay between lipid metabolism, palmitoylation, and immune regulation in hepatocellular carcinoma [54, 55]. These observations suggest that the FASN–palmitoylation axis represents a metabolic–immune regulatory interface that may be exploited for therapeutic intervention in hepatocellular carcinoma. The FASN–palmitoylation axis highlights a potential link between metabolic reprogramming and palmitoylation-dependent signaling in hepatocellular carcinoma. Increased fatty acid synthesis may elevate intracellular palmitate levels, thereby providing substrates for palmitoylation reactions and reinforcing oncogenic signaling networks. Nevertheless, this relationship may not be universally applicable across all tumors, as lipid metabolic pathways are highly heterogeneous among different HCC molecular subtypes. In addition, targeting lipid metabolism could affect systemic metabolic homeostasis, raising concerns about potential metabolic toxicity [56]. These considerations suggest that therapeutic approaches targeting the FASN–palmitoylation axis may require careful patient stratification based on metabolic characteristics and palmitoylation dependency. PHF2-SREBP1c axis Palmitoylation drives metabolic reprogramming through the PHF2–SREBP1c regulatory axis. PA has been implicated in metabolic remodeling of hepatocellular carcinoma cells, including HepG2 and Hep3B models. Recent studies suggest that PA influences lipid metabolic pathways through palmitoylation-dependent regulation of key metabolic regulators. In this context, the palmitoyltransferase ZDHHC-23 promotes palmitoylation of plant homeodomain finger protein 2 (PHF2), which subsequently triggers its ubiquitin-mediated degradation. PHF2 has been reported to function as a tumor-suppressive factor in HCC by negatively regulating lipogenic signaling. One mechanism involves its role in promoting ubiquitination and degradation of sterol regulatory element-binding protein 1c (SREBP1c), a major transcriptional regulator controlling genes involved in fatty acid synthesis. By destabilizing SREBP1c, PHF2 restrains lipogenic transcriptional programs and limits excessive lipid accumulation within tumor cells. When PHF2 stability is compromised through palmitoylation-dependent degradation, SREBP1c activity is correspondingly enhanced, resulting in increased synthesis and accumulation of free fatty acids in hepatocellular carcinoma cells. These metabolic changes may further elevate intracellular palmitate levels, thereby reinforcing palmitoylation-dependent regulatory processes. Together, these findings suggest the existence of a PA-driven feedback mechanism involving the PHF2/SREBP1c axis that contributes to metabolic reprogramming during HCC progression [57]. This regulatory circuit highlights a potential link between palmitoylation-dependent signaling and lipid metabolic reprogramming in HCC. Targeted palmitoylation-based therapeutic strategies Pharmacological strategies targeting palmitoylation pathways Accumulating evidence indicates that dysregulated protein palmitoylation contributes to hepatocellular carcinoma progression by modulating oncogenic signaling pathways, metabolic regulation, and immune checkpoint activity. Consequently, pharmacological modulation of palmitoylation has emerged as a potential therapeutic strategy for disrupting these interconnected processes. Current approaches mainly focus on targeting palmitoyltransferases, depalmitoylating enzymes, or palmitoylation-dependent signaling networks. Representative compounds, their molecular targets, and current research status are summarized in Table 2. Table 2Inhibitors targeting protein palmitoylation in HCC therapyTarget/mechanismInhibitor/typeMode of actionClinical trial status / identifierReference (s)ZDHHC Palmitoyltransferases2-BPBroad-spectrum ZDHHC inhibitor; non-specific palmitoylation blockadePre-clinical trial[59, 60]Anthraquinone derivativesCompetitive inhibition of ZDHHC activityPre-clinical trial[59]Compound VTargets conserved ZDHHC-CRD domainPre-clinical trial[59]PD-L1 (265–279 aa) peptideCompetitively blocks ZDHHC-3 substrate-binding, inhibiting PD-L1 palmitoylationPre-clinical trial[38]ARTSelective ZDHHC-6 inhibition (endoperoxide-mediated)Phase I clinical trial(NCT02304289)[62]APT/PPT/ABHD17 DepalmitoylasesPalm BPan-inhibitor of serine hydrolases (APT family)Pre-clinical trial[64]HDFPIrreversible APT inhibitorPre-clinical trial[65]ABD957Covalent inhibitor of ABHD17 familyPre-clinical trial[66]EzurpimtrostatInhibits PPT1-mediated depalmitoylation; upregulates MHC-I and CD8 + T cellsPhase II clinical trial(NCT05448677)[67]GNS561Targets PPT1; disrupts lysosomal acidification and mTOR signalingPhase II clinical trial(NCT03316222)[69, 70]Other StrategiesPCSK9-derived peptideCompetitively inhibits PCSK9 palmitoylation, suppressing AKT phosphorylationPre-clinical trial[46]SorafenibMulti-kinase inhibitor (RAF/MEK/ERK, VEGFR/PDGFR)Approved, not directly related(NCT01470495、NCT02187081、NCT00703365、NCT00490685、NCT00576056、NCT00044512)[68]PORCN inhibitorsBlocks palmitoleation of Wnt ligands, suppressing oncogenic Wnt pathway activation in a subset of HCC.Phase II clinical trial for other solid tumors (such as pancreatic cancer, head and neck cancer, breast cancer, etc.), but not for HCC(NCT01351103、NCT03507998、NCT03901950)[43, 63] Inhibitors targeting protein palmitoylation in HCC therapy One major therapeutic strategy involves inhibition of ZDHHC palmitoyltransferases. Several broad-spectrum inhibitors of protein palmitoylation have been developed, including 2-bromopalmitate (2-BP), anthraquinone derivatives, and compound V. These agents suppress palmitoylation by interfering with the catalytic activity of ZDHHC enzymes and have been widely used in experimental studies to investigate palmitoylation-dependent signaling. However, their lack of enzyme specificity and potential toxicity limit their clinical applicability, as these inhibitors may also affect other cellular lipid-modifying processes [59–61]. In addition to enzyme-level inhibition, strategies targeting palmitoylation at the substrate level have also been explored. For example, a synthetic peptide derived from the palmitoylation region of PD-L1 has been shown to competitively block ZDHHC3-mediated palmitoylation of PD-L1 [38]. By occupying the substrate-binding site of the enzyme, this peptide reduces PD-L1 membrane localization and stability, thereby enhancing anti-tumor immune responses. Drug repurposing has also provided new opportunities for targeting palmitoylation-related enzymes. Artemisinin (ART), a widely used antimalarial drug, has recently been identified as an inhibitor of ZDHHC6 [62]. Although the specificity of ART toward different ZDHHC enzymes remains to be clarified, this finding suggests that clinically approved compounds may be repurposed to modulate palmitoylation-dependent signaling. In contrast to the limited progress in ZDHHC-targeted drugs, inhibitors of palmitoylation-associated enzymes upstream in lipid signaling have shown greater translational potential. Inhibition of palmitoylation-dependent signaling pathways upstream of palmitoylated proteins has also shown therapeutic potential. PORCN inhibitors, which block palmitoylation of Wnt ligands, have entered clinical trials for several malignancies characterized by Wnt pathway activation. Although their efficacy in HCC remains to be fulldy evaluated, these agents highlight the possibility of indirectly targeting palmitoylation-regulated signaling networks [63]. Another therapeutic strategy involves inhibiting depalmitoylation enzymes. Several compounds targeting acyl-protein thioesterases (APTs) have been reported. For instance, palmostatin B and hexadecyl fluorophosphonate (HDFP) act as broad inhibitors of serine hydrolases that include multiple depalmitoylases [64, 65]. More selective agents are also being developed; for example, ABD957 selectively inhibits members of the ABHD17 depalmitoylase family and has shown potential therapeutic activity in NRAS-mutant cancers [66]. Recent studies have also explored the role of depalmitoylation inhibitors in cancer immunotherapy. Ezurpimtrostat, a selective inhibitor of palmitoyl-protein thioesterase 1 (PPT1), enhances anti-tumor immune responses by increasing MHC-I surface expression and promoting the activation of tumor-infiltrating CD8⁺ cytotoxic T cells. These effects can enhance the efficacy of immune checkpoint blockade therapy in preclinical HCC models, suggesting that modulation of depalmitoylation may help overcome immune evasion mechanisms [67]. Targeting palmitoylation pathways may also synergize with existing anti-cancer therapies. Sorafenib, a multi-kinase inhibitor that blocks RAF/MEK/ERK signaling and inhibits VEGFR/PDGFR-mediated angiogenesis, remains a first-line treatment for advanced HCC [68]. Recent preclinical studies indicate that GNS561, a lysosomotropic small-molecule inhibitor of PPT1, disrupts lysosomal function and suppresses mTOR signaling. Importantly, the combination of GNS561 and sorafenib has demonstrated synergistic anti-tumor effects in HCC models, suggesting that targeting palmitoylation-related pathways may enhance the efficacy of existing targeted therapies [69]. In addition to enzyme-targeting approaches, strategies aimed at disrupting palmitoylation of specific oncogenic proteins have also been proposed. For example, a bioactive peptide derived from PCSK9 has been designed to competitively inhibit PCSK9 palmitoylation, resulting in reduced AKT phosphorylation and suppression of downstream oncogenic signaling. Such substrate-targeted approaches may offer improved specificity compared with global inhibition of palmitoylation enzymes [46]. Another therapeutic direction involves targeting depalmitoylation enzymes. Inhibitors of APT and PPT1 have demonstrated anti-tumor activity by altering the turnover and signaling properties of palmitoylated proteins. For example, Ezurpimtrostat (also known as GNS561), a selective PPT1 inhibitor, disrupts lysosomal function and suppresses mTOR signaling. Preclinical studies have shown that GNS561 exhibits synergistic anti-tumor effects when combined with sorafenib, suggesting that targeting depalmitoylation pathways may enhance the efficacy of existing therapies [69, 70]. Taken together, these approaches illustrate the expanding range of pharmacological strategies aimed at modulating palmitoylation-dependent signaling in hepatocellular carcinoma. However, most of these agents remain in early stages of development, and further studies are required to improve enzyme selectivity, reduce toxicity, and evaluate their therapeutic efficacy in clinical settings [11]. Clinical translation outlook and patient stratification strategies Despite promising mechanistic insights, translating palmitoylation-targeted therapies into clinical practice presents several challenges. One key issue is the identification of reliable biomarkers that can define patient populations most likely to benefit from these therapeutic strategies. Because palmitoylation regulates multiple signaling pathways in a context-dependent manner, therapeutic responses may vary significantly across different molecular subtypes of hepatocellular carcinoma. Potential stratification markers may include the expression levels of specific palmitoyltransferases, the palmitoylation status of oncogenic proteins, or metabolic signatures associated with increased lipid biosynthesis. Tumors characterized by elevated palmitate production or increased activity of particular ZDHHC enzymes may exhibit greater dependency on palmitoylation-mediated signaling, making them more responsive to therapies targeting this modification. Another critical consideration is the potential toxicity associated with systemic inhibition of palmitoylation enzymes. Since palmitoylation regulates numerous physiological processes in normal tissues, non-selective inhibition may disrupt essential cellular functions. Therefore, the development of more selective strategies—such as substrate-specific inhibitors or context-dependent modulation of palmitoylation—may provide a safer therapeutic approach. Beyond monotherapy, rational combination strategies may further enhance therapeutic efficacy. For example, inhibition of palmitoylation-dependent stabilization of immune checkpoint molecules such as PD-1, PD-L1, or TIM-3 may improve the response to immune checkpoint blockade therapies. Similarly, targeting palmitoylation-associated metabolic pathways, including the FASN–ZDHHC regulatory axis, may sensitize tumors to metabolic inhibitors or targeted kinase inhibitors. Overall, integrating molecular profiling, biomarker-guided patient stratification, and rational combination therapies will be essential for translating palmitoylation-targeted interventions into clinical practice. Continued investigation into the molecular determinants of palmitoylation dependency may ultimately enable more personalized treatment strategies for patients with hepatocellular carcinoma. Perspectives and challenges Key insights Although an increasing number of studies have demonstrated that protein palmitoylation contributes to tumor development and progression across multiple cancer types, the extent to which these mechanisms operate in HCC remains incompletely understood. In several malignancies, palmitoylation-dependent pathways have been linked to oxidative stress regulation, metabolic adaptation, and therapeutic response. For example, disruption of specific ZDHHC enzymes has been shown to enhance the efficacy of chemotherapy in breast cancer by increasing oxidative stress and suppressing tumor cell proliferation [71, 72]. However, whether similar mechanisms are conserved in HCC has not yet been clearly established. These observations suggest that the functional roles of palmitoylation may vary substantially across tumor types and highlight the need for systematic comparative studies to determine how these regulatory mechanisms operate within the unique metabolic and immunological environment of liver cancer. Despite rapid progress in this field, several key questions remain unresolved. Current knowledge of palmitoylation in cancer biology has largely been derived from studies focusing on individual substrates or specific signaling pathways, which may limit broader interpretation of its biological functions. Importantly, members of the ZDHHC palmitoyltransferase family appear to exert diverse and sometimes opposing roles in tumor biology. While certain enzymes, such as ZDHHC-19 and ZDHHC-20, have been associated with oncogenic signaling and tumor progression, others—including ZDHHC6—have been reported to display tumor-suppressive activities in particular contexts. These findings indicate that the functional consequences of palmitoylation are highly context-dependent and cannot be simply classified as either pro-tumorigenic or anti-tumorigenic.Moreover, the majority of ZDHHC family members remain poorly characterized in hepatocellular carcinoma. Among the 23 known human ZDHHC enzymes, only a subset has been investigated in relation to HCC progression. The biological functions of many others, such as ZDHHC-8 and ZDHHC-14, have not yet been systematically examined. Elucidating the roles of these understudied enzymes will be essential for constructing a comprehensive understanding of palmitoylation-regulated signaling networks in liver cancer and determining whether individual ZDHHC proteins function as oncogenic drivers or tumor suppressors. Another major challenge arises from the broad substrate specificity of ZDHHC enzymes [73]. Because many palmitoyltransferases can modify overlapping sets of proteins, attributing a particular cellular phenotype to the activity of a single ZDHHC enzyme may be difficult. Functional redundancy among family members may also enable compensatory mechanisms that obscure the contribution of individual enzymes. Furthermore, many existing studies rely heavily on overexpression or knockdown approaches, which can introduce off-target effects and limit the interpretation of causal relationships. These limitations highlight the importance of developing more precise experimental strategies for investigating palmitoylation-dependent signaling. Recent methodological advances have begun to address these challenges. Proteomic approaches such as acyl-biotin exchange (ABE) and acyl-resin-assisted capture (acyl-RAC) have enabled large-scale identification and enrichment of palmitoylated proteins [74–76]. When combined with chromatographic separation and mass spectrometry analysis, these techniques allow quantitative characterization of palmitoylation dynamics within cellular systems [77, 78]. In parallel, bioorthogonal lipid probes have facilitated visualization of palmitoylated proteins in living cells, providing insights into their spatial distribution and trafficking behavior. Emerging imaging technologies, including multiplex fluorescence resonance energy transfer–based approaches, further enable real-time monitoring of palmitoylation processes at subcellular resolution [79, 80]. In parallel, bioorthogonal lipid probes have facilitated visualization of palmitoylated proteins in living cells, providing insights into their spatial distribution and trafficking behavior. Emerging imaging technologies, including multiplex fluorescence resonance energy transfer–based approaches, further enable real-time monitoring of palmitoylation processes at subcellular resolution [81]. Together, these methodological developments are providing powerful platforms for dissecting the functional landscape of the palmitoylome. Beyond its established roles in signaling and metabolism, palmitoylation has recently been implicated in the regulation of ferroptosis, a form of regulated cell death characterized by lipid peroxidation [82]. Although the mechanistic relationship between palmitoylation and ferroptosis in hepatocellular carcinoma is still emerging, several lines of evidence suggest that palmitoylated proteins may influence cellular sensitivity to ferroptotic stress. For instance, palmitoylation of the cystine/glutamate antiporter subunit xCT (SLC7A11) has been reported to stabilize its membrane localization and enhance antioxidant defense, thereby reducing susceptibility to ferroptosis-inducing agents in certain cancer models [83–85]. Conversely, depalmitoylation of enzymes involved in phospholipid metabolism, such as ACSL4, may alter lipid peroxidation dynamics [86]. Validating this model will necessitate future studies that integrate palmitoylome-wide profiling during ferroptotic induction with functional genetic approaches to delineate causal mechanisms within the specific pathological context of HCC. Unraveling this interplay is poised to open new avenues for rational combination therapies that concurrently target palmitoylation pathways and inducers of ferroptosis [87]. This potential interaction is particularly relevant in hepatocellular carcinoma, a malignancy characterized by extensive lipid metabolic reprogramming and a lipid-rich cellular environment. Variations in membrane lipid composition are known to influence ferroptotic sensitivity, suggesting that palmitoylation of membrane-associated proteins could play a role in determining ferroptosis susceptibility in HCC cells. Future investigations integrating global palmitoylation profiling with functional genetic approaches during ferroptotic stress may help clarify the mechanistic connections between these processes. Understanding this interplay could ultimately provide new opportunities for developing combination therapeutic strategies that simultaneously target palmitoylation pathways and ferroptosis induction. Current challenges Targeting protein palmitoylation and its associated enzymes represents an emerging therapeutic strategy for hepatocellular carcinoma; however, several fundamental challenges remain. One major limitation is the incomplete characterization of enzyme–substrate relationships within the palmitoylation network. The full spectrum of substrates for ZDHHC palmitoyltransferases and depalmitoylating enzymes such as APTs and PPTs has not yet been comprehensively defined, and the molecular determinants governing substrate recognition remain poorly understood [88]. Addressing this knowledge gap will require advanced screening approaches capable of systematically identifying palmitoylated proteins and mapping their regulatory interactions. A more detailed understanding of these enzyme–substrate networks will be essential for clarifying how palmitoylation regulates key signaling pathways in hepatocellular carcinoma and for identifying new therapeutic vulnerabilities. From a drug development perspective, selectively targeting ZDHHC enzymes presents substantial difficulties. Members of the ZDHHC family share a highly conserved catalytic architecture characterized by the signature DHHC motif embedded within a cysteine-rich domain and surrounded by multiple transmembrane segments. This conserved structural framework—particularly the hydrophobic acyl-CoA binding pocket adjacent to the catalytic cysteine residue—limits the feasibility of designing isoform-specific small-molecule inhibitors. Although variable cytoplasmic loops and C-terminal regions may participate in substrate recruitment and regulatory interactions, their contribution to isoform-selective drug targeting remains insufficiently defined [59]. Furthermore, the lack of clearly defined substrate-recognition motifs unique to individual ZDHHC enzymes further complicates the development of selective inhibitors. As a result, only a limited number of compounds specifically targeting ZDHHCs, depalmitoylases, or palmitoylated effector proteins have been identified to date. Overcoming these challenges will be critical for translating the growing mechanistic understanding of palmitoylation into effective therapeutic strategies for hepatocellular carcinoma. Future directions Because multiple palmitoyltransferases can modify the same protein, while individual enzymes are capable of acting on numerous substrates, therapeutic strategies based on inhibition of a single palmitoyltransferase may not effectively suppress palmitoylation of a specific target protein. Instead, approaches that directly interfere with the palmitoylation process of particular substrates—by exploiting structural or sequence features unique to the target protein—may represent a more promising direction for developing selective palmitoylation-based therapies. Looking ahead, integrating complementary technologies such as advanced imaging, high-resolution mass spectrometry, genetic screening platforms, and structural biology approaches will be essential for defining the regulatory architecture of palmitoylation in both physiological and pathological contexts. These multidisciplinary strategies are expected to provide a stronger mechanistic foundation for translating palmitoylation biology into therapeutic interventions [89]. Clinical translation obstacles Despite increasing interest in targeting protein palmitoylation for cancer therapy, several barriers still hinder its translation into clinical applications. A major challenge lies in achieving sufficient target selectivity. Many currently available inhibitors act broadly on palmitoylation-related enzymes, including members of the ZDHHC family, and therefore may interfere with essential cellular processes in normal tissues. Such non-specific inhibition can result in off-target toxicity and limit the therapeutic window. In addition, tumor cells may adapt to pharmacological perturbation of palmitoylation by remodeling metabolic pathways that supply lipid substrates or compensate for disrupted signaling networks, potentially reducing the long-term effectiveness of these therapies [90]. Another complexity arises from the context-dependent roles of palmitoylation in tumor biology. Depending on the cellular environment and specific substrates involved, palmitoylation can either promote tumor progression or exert tumor-suppressive effects. This functional diversity suggests that therapeutic strategies targeting palmitoylation will likely require careful stratification of disease context and molecular background. Furthermore, the broad substrate spectrum of palmitoyltransferases presents an additional obstacle for drug development. Because individual enzymes can modify numerous proteins with overlapping functions, systemic inhibition may influence multiple signaling pathways simultaneously, increasing the risk of unintended biological consequences and complicating prediction of therapeutic outcomes [73]. In summary, protein palmitoylation represents an important regulatory interface linking lipid metabolism, signal transduction, and cellular homeostasis in hepatocellular carcinoma. By modulating the dynamic palmitoylation status of key proteins, this modification influences diverse oncogenic pathways and metabolic processes. Continued investigation into the molecular mechanisms governing palmitoylation may therefore facilitate the development of more precise therapeutic strategies aimed at exploiting this regulatory network for hepatocellular carcinoma treatment. Author contributions Fang Wei, Zi qing Zhu drafted the manuscript via an intense literature survey and made the figures; Yu Meng contributed to the conception and preparation of the manuscript; Fang Wei made the tables; Dan-Xia Zhu and Yueping Shen reviewed and edited the manuscript; Jun Wu and Dan-Xia Zhu supervised the manuscript. Funding The research was supported by the Science and technology project of Changzhou Municipal Health Commission (QY202301) and Changzhou Science and Technology Bureau (CJ20243007). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. This is a review article and does not involve any new studies with human participants or animals conducted by the authors. This is a review article and no human participants were involved in new research by the authors. Consent for publication Not applicable. This is a review article and does not contain any individual person’s data in any form. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Fang Wei and Zi qing Zhu have contributed equally to this work and and share first authorship. Contributor Information Dan-Xia Zhu, Email: zhudanxia66@163.com. Jun Wu, Email: wujun68@sina.com. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.